Genelux (GNLX) Other Non-Current Liabilities (2022 - 2023)
Genelux (GNLX) posted quarterly Other Non-Current Liabilities of $321000.0 for Q4 2023, up 89.94% year-over-year from $169000.0 in Q4 2022, and up 89.94% quarter-over-quarter from $169000.0 in Q4 2022.
Genelux (GNLX) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends
Genelux's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $321000.0 for Q4 2023.
- In Q4 2023, Other Non-Current Liabilities rose 89.94% year-over-year to $321000.0; the TTM figure through Dec 2023 stood at $321000.0 (up 89.94% YoY), while the FY2023 annual figure was $321000.0, up 89.94% from the prior year.
- Other Non-Current Liabilities for Q4 2023 stood at $321000.0, up from $169000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $321000.0 in Q4 2023, with the low at $169000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 321,000.00 |
| Dec 31, 2022 | 169,000.00 |